ICH Q11 Draft Gelling On Lifecycle/Change Management and Control Strategy Components

Recommendation

23-26 April 2024
Berlin, Germany

Computerised System Validation - Introduction to Risk Management + GAMP 5 Approach
Learn How to Plan, Implement and Document Effectively Computer Validation Activities

The lifecycle management section of the newest working draft of ICH's Q11 guideline on drug substance development and manufacturing provides allowance for applicants to include change management proposals in their original submissions.

The issue of post-approval changes has been a challenging one for the Q11 Expert Working Group (EWG) to address, given the differing legislative/regulatory frameworks in the regions that need to be accommodated.  The ICH mandate proscribes against including in its guidelines anything that would require a legal change to implement.

However, the rapporter for Q11, Brian Withers (Abbott UK), reported at the CASSS/FDA Well-Characterized Biotechnology Pharmaceutical (WCBP) conference in Washington, D.C. on January 12 that the three regions had agreed to include a provision in the guideline that applicants could make proposals in the original submission for how they would "make specific changes to their product in a post-approval setting."

Noting that providing flexibility within the lifecycle section to manage change was high on the industry wish list, Withers pointed to the revision as "some way along the route that we were, from the industry point of view certainly, looking for."  The guideline, he noted, also includes the ICH Q8R provision that moving within the approved design space doesn't require a regulatory approval.

The handling of the post-approval change issue was part of the compromise between industry and regulators that the ICH process embodies, Withers commented.

To read the complete story, please see the ECA website members' area.

Source: This article is taken from the IPQ (International Pharmaceutical Quality Journal).

IPQ’s monthly format keeps subscribers "Inside the Global Regulatory Dialogue"™ where the initiatives are being defined that will reshape the landscape. The IPQ is one of the most important Journals in the GMP and regulatory environment. In co-operation with IPQ the ECA publishes selected articles in the members’ area on the ECA website. Members also benefit from a special agreement with IPQ´s Editor in Chief Bill Paulson: an exclusive subscription fee for the IPQ Journal. You will find more information in the members’ area.

To find out more about IPQ, please visit the IPQ website.